Tirzepatide (Research Overview)
(Research Overview)
Mechanism of Action
Tirzepatide is a synthetic dual agonist peptide engineered to activate both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). The molecule is based on the native GIP sequence with modifications that confer GLP-1R binding affinity, creating a single molecule capable of engaging both incretin pathways simultaneously.
GLP-1R activation promotes glucose-dependent insulin secretion, suppresses glucagon release, and engages central appetite-regulating circuits. GIPR co-agonism has been studied for its potential to amplify or modulate these effects — particularly with respect to gastrointestinal tolerability and adipose tissue signaling. Researchers have proposed that GIPR engagement may reduce the nausea associated with GLP-1R monotherapy.
Research Areas
Tirzepatide has been one of the most extensively studied dual incretin agonists in recent metabolic research. Large-scale clinical trials have examined its effects on glycemic control, body weight, and cardiovascular risk markers. Published data from the SURPASS and SURMOUNT trial programs have provided detailed pharmacodynamic and safety profiles across diverse study populations.
Beyond glycemic endpoints, researchers have investigated Tirzepatide's effects on hepatic steatosis, lipid profiles, blood pressure, and inflammatory markers. The compound's dual mechanism has also been studied in the context of heart failure with preserved ejection fraction (HFpEF) and sleep apnea, reflecting broader interest in incretin receptor biology beyond metabolic disease.
Preclinical research has explored GIPR/GLP-1R co-agonism in models of neuroinflammation, bone metabolism, and reproductive biology, suggesting that incretin receptor signaling may have physiological roles extending well beyond glucose homeostasis.
Specification summary
Tirzepatide
Our Tirzepatide research compound is a dual GLP-1/GIP agonist peptide. Stated purity ≥99%. For laboratory research use only.
Related materials
References
- Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PMID 30473097 · DOI
- Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17). PMID 32730231 · DOI
- Borner T, Geisler CE, Fortin SM, Cosgrove R, Alsina-Fernandez J, Dogra M, et al. GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models. Diabetes. 2021;70(11):2545-2553. PMID 34380697 · DOI
- Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID 34170647 · DOI
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID 35658024 · DOI
- Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205. PMID 38912654 · DOI
- Müller TD, Adriaenssens A, Ahrén B, Blüher M, Birkenfeld AL, Campbell JE, et al. Glucose-dependent insulinotropic polypeptide (GIP). Mol Metab. 2025;95:102118. PMID 40024571 · DOI
Cited literature is provided for scientific context only and does not describe or endorse any use of these products.
For laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.